Topics

Lab of the Future Congress USA, 19–20th May 2020, Boston MA.

08:43 EST 3 Feb 2020 | Zyme Communications
  • USA congress showcasing research innovation in the life sciences
  • Follows successful European event in Cambridge, UK

Cambridge, UK, and Boston, MA, USA, 03 February 2020: Open Pharma Research, a platform for information exchange and networking in the life sciences, today announced the introduction of Lab of the Future USA. The event will see major life science and pharmaceutical companies, research institutes and service companies gather on the 19­–20th May 2020 at Hilton Back Bay in Boston, USA. The event follows the highly successful Lab of the Future Europe event, which saw more than 300 senior pharma executives meet to discuss the latest advancements in the life science industry.

The Lab of the Future series was set up to provide access to the people and resources for life science companies to continue thriving in a rapidly-evolving world. Technology, people and infrastructure are becoming increasingly important to drive new thinking in the lab to deliver on increased R&D productivity. Lab of the Future USA will provide a platform for life science research, laboratory and technology leaders to help shape new strategy, network with peers, and hear of innovative solutions from the major service providers in this space.

Over 80 speakers are expected, with confirmed headline speakers from leading global pharma and research institutes, including:

·        Sir Mene Pangalos, Executive VP & President of Biopharmaceuticals R&D, AstraZeneca
·        Carol Rohl, Executive Director, Global Research IT, Merck Research Laboratories
·        Hal Stern, VP & Chief Information Officer of R&D, Janssen
·        Lesley Solomon, SVP Innovation, Chief Innovation Officer, Dana-Farber Cancer Institute
·       Andreas Matern, Head of Digital Translational Medicine, Sanofi

The event is supported by The Pistoia Alliance: the global, not-for-profit members’ life science organisation working to lower barriers to innovation in R&D through pre-competitive collaboration (www.pistoiaalliance.org).

Sponsors confirmed to date include Millipore Sigma, Avantor, L7 Informatics, SciBite, Riffyn and ACD/Labs.

Zahid Tharia, Founding Director, Open Pharma Research, said: “We are thrilled to be bringing the Lab of the Future Congress to Boston, the largest life sciences hub in the world. The event will be a continuation of the discussions held in Cambridge, UK on how to turn the lab of the future from concept to reality. Our goal is to help drive the successful incorporation of new technologies and thinking into the lab to enable collaboration, foster innovation and deliver new medicines. By bringing a diverse range of experts together in Boston, we’d like to think we’re doing our bit to help achieve this. We hope you can join us there.”

For more information, please visit: www.lab-of-the-future.com/USA/

ENDS

Notes to Editors:

The Lab of the Future USA follows a highly successful event of the same name in Cambridge, UK

Sir Mene Pangalos, Executive VP & President Biopharmaceuticals R&D, AstraZeneca
Carol Rohl, Executive Director, Global Research IT, Merck Research Laboratories
Hal Stern, VP & Chief Information Officer of R&D, Janssen
Lesley Solomon, SVP Innovation, Chief Innovation Officer, Dana-Farber Cancer Institute
Andreas Matern, Head of Digital Translational Medicine, Sanofi


For high-resolution images, please contact Zyme Communications.

For further information please contact:

Zyme Communications
Lorna Cuddon
Tel: +44 (0)7811 996 942
E-mail: lorna.cuddon@zymecommunications.com

Open Pharma Research www.openpharmaresearch.com

Open Pharma Research helps to foster collaboration in bioscience research by providing a platform for information exchange, networking and the spread of best practice. Through case study interviews, webinars and conferences we provide the industry with a focal point to share information, find solutions and drive innovation in life science research.

In the post-blockbuster era of distributed scientific research, digitisation and automation; disruptive thinking is necessary to push advances in the lab to the patient with speed and efficiency.

At Open Pharma Research, we believe that the successful collaboration between the biopharmaceutical industry, public health bodies, biotech companies, service providers and regulators is crucial to the success in the next era of R&D innovation in healthcare.

Follow the Lab of the Future Congress on Twitter @LabOfTheFuture and LinkedIn @LaboftheFutureCongress

NEXT ARTICLE

More From BioPortfolio on "Lab of the Future Congress USA, 19–20th May 2020, Boston MA."

Quick Search

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...